- Conditions
- Metabolic Syndrome, Coronary Microvascular Dysfunction
- Interventions
- Vericiguat, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 18
- States / cities
- Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
- Conditions
- Chronic Heart Failure With Preserved Ejection Fraction
- Interventions
- Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Carmichael, California • West Hills, California + 26 more
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat (BAY1021189) 5 mg
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more
- Conditions
- Heart Failure, Left Ventricular Systolic Dysfunction
- Interventions
- Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 29 Days to 17 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more